NAXD deficiency: how vitamin B3 could help
Official title: Understanding and Treating NAXD Deficiency Using Vitamin B3-Based Approaches
Funded at J. David Gladstone Institutes · NIH-11380760 · Data updated 2026-11-12
A study in mice and related experiments tests whether vitamin B3-based approaches can prevent problems caused by NAXD deficiency and improve organ function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 1, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $574,921 |
| NIH project number | 5R01NS142087-02 |
| Project ID | NIH-11380760 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with or at risk for NAXD deficiency or related NAD+ metabolism disturbances.
✕Less likely to help
Populations without NAD+ metabolism disorders are unlikely to benefit from these specific approaches.
What this research studies
This project uses a NAXD knockout mouse model to understand how NAXD deficiency affects organs like the brain, heart, and skin. It also looks at how NAD+ metabolism and NADHX buildup may drive disease, and explores potential dietary and vitamin B3-based interventions. The team aims to identify which symptoms could improve with B3 megadoses or serine supplementation and to map disease mechanisms driving these outcomes. The goal is to build a framework for how vitamin therapies might help people with NAXD-related conditions in the future.
Why it matters
Potential benefit: If successful, the work could point to vitamin-based strategies to reduce organ damage in NAXD-deficient patients and guide future clinical trials.
How similar studies have gone: Previous work with vitamin B3 therapies has shown promise in mitochondrial-related conditions, but the NAXD focus is novel and exploratory.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: Jain, Isha Himani — J. David Gladstone Institutes
- Study coordinator: Jain, Isha Himani
Related research
Other NIH-funded projects on the same topics.
-
HOPE: a new approach to silencing HIV and preventing rebound
A large NIH grant is testing a combination strategy to turn off HIV genes in people on treatment so the virus stays gone and health improves.
-
Undo HIV: Understanding and targeting the active HIV reservoir
Aims to map and ultimately eliminate the HIV cells that stay active despite therapy to improve long-term control of HIV in people living with HIV.
-
TREM2 and TYROBP in Alzheimer's brain network changes
This grant looks at how microglial proteins TREM2 and TYROBP influence brain network excitability in people with Alzheimer's disease and related dementias.
-
Commensal respiratory viruses and how they interact with the human airway
A small NIH grant is exploring how the normal viruses living in our airways interact with our cells to stay harmless and support healthy breathing.
-
Targeted delivery systems to edit blood stem cells
Aims to safely deliver genome-editing tools to blood stem cells to treat diseases like acute myeloid leukemia.
-
Regionally Specific Transplants to Restore Breathing After Cervical Spine Injury
A patient-focused look at a study that aims to repair breathing circuits after cervical spinal cord injury using stem-cell–derived nerve cells and targeted neuromodulation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.